ArticleInvestigational new drugs2020

Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.

Yanrong Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.